Atherosclerosis Market Forecasts to 2030 – Global Analysis By Type (Plaque Growth, Plaque Rupture, Endothelial Damage and Immune Response, Fatty Streak and Other Stages), Treatment, Route of Administration, Distribution Channel, Diagnosis, End User and By

Atherosclerosis Market Forecasts to 2030 – Global Analysis By Type (Plaque Growth, Plaque Rupture, Endothelial Damage and Immune Response, Fatty Streak and Other Stages), Treatment, Route of Administration, Distribution Channel, Diagnosis, End User and By Geography

According to Stratistics MRC, the Global Atherosclerosis Market is growing at a CAGR of 4.24% during the forecast period. Atherosclerosis is the term used to describe the gradual hardening and construction of your arteries brought on by cholesterol plaques lining them. The use of medications to treat high blood pressure and high cholesterol will reduce, if not stop, atherosclerosis. They lessen your risk of experiencing a heart attack or stroke. Bypass surgery includes utilizing a vascular from another region of body or a synthetic tube to redirect blood around a blocked or constricted artery. To dissolve a blood clot, thrombolytic treatment involves injecting a drug into the affected artery. Atherectomy is the process of removing plaque from your arteries using a catheter with a cutting edge at one end.

According to the European Heart Network, cardiovascular disease affects 3.9 million people in Europe each year, with over 1.8 million people dying in the European Union.

Market Dynamics

Driver

Increasing prevalence of cardiovascular diseases

It is predicted that the market would develop faster due to the increased frequency of cardiovascular disorders worldwide. Sedentary lifestyles are to blame for the highest incidence of cardiovascular disease in developed nations. Additionally, a rise in the elderly population and a sedentary lifestyle that results in a high frequency of cardiovascular illnesses and growing awareness of available treatments is predicted to boost the market under study.

Restraint

Side effects associated with atherosclerosis


The risk of cardiovascular events like heart attacks and strokes is increased by atherosclerosis. These occurrences may result in death or serious disability. Peripheral artery disease may be brought on by atherosclerosis in the arteries of the extremities, particularly the legs. This may result in discomfort, numbness, and trouble walking. This can put more stress on the cardiovascular system by making arteries less elastic and raising blood pressure. Growth of the market is anticipated to be hampered by the adverse effects of atherosclerosis and the low effectiveness.

Opportunity

Increasing infrastructure spending for healthcare

The increase in healthcare spending, which aids in enhancing its infrastructure, is the element driving the market's growth rate. By boosting funds, a number of government agencies seek to enhance the healthcare infrastructure. Rising awareness-raising efforts by both governmental and private organizations, an increase in disposable income, and the high incidence of high blood pressure are other key elements that are projected to boost the market's growth rate throughout the course of the forecast year.

Threat

High cost of treatment

The continuing treatment of atherosclerosis using prescription drugs, diagnostic exams, and surgical procedures is necessary. These medical treatments can be quite expensive for both individuals and families. Furthermore, the costs of hospitalization, surgery, and rehabilitation are frequently significant when addressing side effects including heart attacks and strokes. To treat their illness and lower the risk of complications, many people with atherosclerosis need medication. The market expansion is being constrained by the cost and potential duration of use of these treatments.

Covid-19 Impact

The COVID-19 pandemic had a detrimental effect on the market for atherosclerosis medications since it delayed financing from several firms involved in research and development as well as investments in innovative atherosclerosis therapies that target the disease. Additionally, the pandemic had a detrimental effect on the atherosclerosis clinical studies that were in progress, which hampered the expansion of the worldwide market for atherosclerosis medications as a result of the delayed clinical trials.

The oral segment is expected to be the largest during the forecast period

The oral segment is expected to be the largest during the forecast period. This is due to a rise in knowledge about routine cholesterol testing and therapy as well as sedentary lifestyles that have been linked to the onset of other ailments, including diabetes. Additionally, the mucosal permeability, drug solubility, and environmental stability in the gastrointestinal tract are benefits of oral medications. As a result, their demand is larger, which helps the market share growth of medications for atherosclerosis.

The retail pharmacy segment is expected to have the highest CAGR during the forecast period

The retail pharmacy segment is expected to have the highest CAGR during the forecast period. This is linked to a growth in the desire for buying medications from drug shops and retail pharmacies owing to the availability of cheap and reasonably priced medications as well as the simplicity of obtaining cardiovascular medications in these pharmacies. Additionally, customers who visit retail pharmacies and drug shops to buy atherosclerosis meds benefit from the ability to learn all there is to know about the prescriptions, which serves to fuel the segment's expansion.

Region with largest share

North America is projected to hold the largest market share during the forecast period due to increase in government and private sector efforts to promote healthy lifestyles. The market is anticipated to increase as a result of the well-established healthcare infrastructure, strong buying power, and rising acceptance of atherosclerosis treatment products. In addition, rising cardiovascular disease incidence in the area and increased public awareness of disease prevention are driving up demand for atherosclerosis medications and propelling the market's expansion.

Region with highest CAGR

Asia Pacific is projected to hold the highest CAGR over the forecast period. This is due to the presence of pharmaceutical businesses in the area as well as the increase in the purchasing power of populous nations. The market is expanding as a result of the growing number of elderly people who are suffering from different cardiovascular ailments. Additionally, because of the huge population base, unmet medical demands, and rise in disposable income, it has a great growth potential. Additionally, a profitable market is created by the expansion of medical tourism and growing healthcare infrastructure.

Key players in the market

Some of the key players in Atherosclerosis Market include Boehringer Ingelheim International GmbH., Bayer AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Lupin, GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd. , Allergan, F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Sanofi, Allergan, Eli Lilly and Company, AbbVie Inc., Amgen Inc., Gilead Sciences, Inc., Hikma Pharmaceuticals PLC, Johnson & Johnson Private Limited, AstraZeneca, Merck & Co., Inc. and Mylan N.V.

Key Developments

In September 2022, Novo Nordisk has entered into a new strategic cooperation with Microsoft to accelerate medication research and development via the use of big data and artificial intelligence (AI). The team will employ artificial intelligence to construct models that can predict a person's risk of getting atherosclerosis or arterial plaque development.

In August 2022, AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the European Commission (EC) has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) and HER2-negative high-risk early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy.

In December 2021, Novartis announced the US Food and Drug Administration (FDA) approval of Leqvio, the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol with two doses a year, after an initial dose and one at three months.

Stages Covered
• Plaque Growth
• Plaque Rupture
• Endothelial Damage and Immune Response
• Fatty Streak
• Other Stages

Treatments Covered
• Medication
• Surgery
• Other Treatments

Route of Administrations Covered
• Parenteral
• Oral

Distribution Channels Covered
• Retail Pharmacy
• Online Pharmacy

Diagnosis Covered
• Doppler Ultrasound
• Blood Tests
• Ankle-brachial Index (ABI)
• Echocardiogram
• Electrocardiogram (ECG)
• Other Diagnosis

End Users Covered
• Specialty Clinics
• Homecare
• Hospitals
• Other End Users

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements